ahlam1399
09-07-2015, 02:48 PM
UK backs use of Merck cancer immu**therapy after price discount
LONDON, Sept 7 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immu**therapy drug Keytruda, after the U.S. drugmaker promised to supply it to... http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=NL**nRdmhFE:483xVp_TF0I:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=NL**nRdmhFE:483xVp_TF0I:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/NL**nRdmhFE
LONDON, Sept 7 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immu**therapy drug Keytruda, after the U.S. drugmaker promised to supply it to... http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:yI l2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=NL**nRdmhFE:483xVp_TF0I:V_ sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:V_ sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/governmentfilingsNews?i=NL**nRdmhFE:483xVp_TF0I:F7 zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/governmentfilingsNews?a=NL**nRdmhFE:483xVp_TF0I:F7 zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/governmentfilingsNews/~4/NL**nRdmhFE